S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

Invitrogen’s Broader Stem Cell Monitor Kit (IVGN)

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Invitrogen Corp. (NASDAQ:IVGN) has announced the launch of a new kit that allows researchers to quickly and reliably monitor the state of human embryonic stem cells. The STEMPRO® EZChek™ Multiplex PCR Kit allows scientists to monitor stem cells with one reaction, using fewer sample cells than ever before. The STEMPRO® EZChek™ Kit allows for the analysis of four early differentiation markers using a small sample and a single-tube reaction. Without the kit, researchers need to carry out five separate reactions in five tubes, using many more cells.

Invitrogen is already the leader or one of the leaders with more than $300 million per quarter in revenues in supplying tools and reagents for stem cell research with more than 1,200 products in the related market.  This may be a much broader consolidated test solution, but with a portfolio that wide it may just be another day at the office.

The stock has not seen any noticeable trading pre-market.  Its market cap as of Friday’s $83.90 close was $3.89 Billion, and the 52-week range is $54.70 to $84.14.

Jon C. Ogg
October 8, 2007

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month
Drew Wood |

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month
Why The Money Guy's 25% Savings Rule Actually Starts at 15%
Ian Cooper |

Why The Money Guy's 25% Savings Rule Actually Starts at 15%

Continue Reading

Douglas A. McIntyre |

Super Tuesday Election Winner: STEM CELLS (STEM, GERN, ASTM, IVGN, KOOL, NBS, OSIR)

Despite not knowing whom the ultimate winner of the 2008 Presidential election will be, it looks like stem cells may…
Jon C. Ogg |

Implosion Day at Geron

Geron Corp. (NASDAQ: GERN) has spent much of the past decade migrating from the key stem cell research player into…
Douglas A. McIntyre |

Stem Cell Research & Cloning Get Some Potential Fresh Air

Stock Tickers: STEM, GERN, ASTM, VIAC, KOOL, CCELThere are some fresh developments that can affect the prices of stocks that…
Jon C. Ogg |

Revisiting CryoPort, Long-Term Opportunity & Risk (CYRX)

CryoPort, Inc. (CYRX) has been long-forgotten by many investors.  The question is whether or not it should be forgotten or…
Douglas A. McIntyre |

Geron Positive Spinal Cord Injury Data (GERN)

Geron Corp. (NASDAQ:GERN) is trading up in pre-market activity on news that would have been much more eagerly received back…
Douglas A. McIntyre |

GE Taking Decisive Step Into Stem Cells (GE, GERN, STEM, ASTM)

General Electric Company (NYSE: GE) is taking a bold and controversial new step into the field of embryonic stem cell…
Jon C. Ogg |

Celgene Gets OncoMed Cancer Pipeline, Maybe Dirt Cheap

OncoMed Pharmaceuticals just went from being an obscure biotech to one on the map with more security than it had.…
Jon C. Ogg |

Stem Cells Versus The Constitution (GERN, STEM, ASTM, CYTX, NBS, BTIM)

Stem cell stocks are getting hit pretty hard this Tuesday.  On Monday came a ruling from a U.S. district judge…
Douglas A. McIntyre |

An Unexpectly Benign View of China

A recent Gallup poll showed that most Americans view the Chinese economy as more powerful than America’s. The media regularly reports…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618